Is Adipotide Peptide a weight-loss peptide found in adipose tissue blood vessels?

In the field of obesity and metabolic disease research, Adipotide Peptide is a revolutionary synthetic chimeric peptide developed by MD Anderson Cancer Center in 2004. Its core design concept is to cut off blood supply to adipose tissue and induce ischemic apoptosis in adipocytes, completely different from traditional appetite suppressants or metabolic regulators used for weight loss. This peptide is composed of a targeting cyclic peptide and an apoptosis-prone linear peptide linked by a short connecting region. It has a molecular weight of approximately 2460 Da, and its industrial form is a white lyophilized powder with moderate water solubility and high stability.

🔬Chimeric molecules induced by angiogenesis and apoptosis

Chemically, Adipotide peptide is a bifunctional chimeric peptide fused together with two functional modules: homing and killing. Its structural sequence is Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys-NH₂-(KLAKLAK)₂, typically existing in a cyclic form and linked to an apoptosis-inducing peptide via a Gly-Gly flexible linker. The nine N-terminal amino acid residues form a disulfide-bonded cyclic structure, constituting the adipose tissue homing peptide. This cyclic structure, stabilized by intramolecular disulfide bonds, imparts protease resistance and conformational rigidity, forming the structural basis for its specific recognition of adipose blood vessels.

 

The C-terminal apoptosis-inducing peptide (KLAKLAK)₂ is a cationic amphiphilic α-helical peptide. This sequence consists of repeating leucine and lysine residues, carrying a positive charge at physiological pH, enabling electrostatic interactions with the negatively charged inner mitochondrial membrane. Once inside the cell, this peptide directly disrupts the integrity of the mitochondrial membrane, inducing the release of cytochrome c and initiating apoptosis. Due to its extremely low penetration of the plasma membrane of normal cells, its toxicity is highly dependent on homing peptides delivering the molecule to the target cell surface, followed by internalization into the cell. This prodrug-like design spatially confines the activity of adipotide to adipose tissue vascular endothelial cells, minimizing off-target toxicity to other tissues.

 

Physically, adipotide peptide, as an investigational chemical, is typically supplied as a white to off-white lyophilized powder with a purity of at least 95% or 98%. It is readily soluble in sterile water and should be stored at -20°C or -80°C in a sealed container protected from light. Repeated freeze-thaw cycles should be avoided after reconstitution. Its molecular weight is approximately 1900-2000 Da, classifying it as a medium-to-short chain peptide, and it can be mass-produced using standard solid-phase peptide synthesis techniques. As a cyclic peptide, the correct disulfide bond pairing of Adipotide directly affects its biological activity and stability; therefore, quality control must include the detection of residual free thiol groups using Ellman's reagent.

 

Structurally, Adipotide Peptide belongs to the "vascular targeting peptide" family. Its homing peptide moiety was initially screened from a random peptide library using phage display technology. It specifically binds to the prohibitin protein, which is highly expressed on adipose tissue vascular endothelial cells. Prohibitin is a mitochondrial membrane protein ubiquitous in various cell types, but it is abnormally highly expressed on the membranes of adipose vascular endothelial cells in obese individuals. This finding provides the target basis for the "selectivity" of Adipotide Peptide.

🧬Obesity and metabolic disease research, fat angiogenesis, drug development

The core applications of Adipotide peptide revolve around targeted clearance of adipose blood vessels, induction of adipocyte apoptosis, and correction of systemic metabolic disorders. Spanning multiple directions including basic theoretical research, animal disease model construction, innovative drug development, and interdisciplinary mechanism exploration, it is an indispensable experimental tool and lead ingredient in the fields of adipose biology and metabolic disease research.

 

In basic research on obesity and adipose blood vessel biology, this peptide is a standard inducing agent for elucidating pathways regulating adipose tissue angiogenesis, cell homeostasis, and apoptosis. Researchers use it to selectively clear the white adipose microvascular network in experimental animals, continuously observing changes in adipocyte morphology, tissue inflammatory infiltration, and lipid metabolism, thereby clarifying the intrinsic connection between adipose tissue and the systemic metabolic system. Simultaneously, it is used to compare the differences in vascular receptor expression between white and brown adipose tissue, delving into the molecular basis of targeted recognition in adipose tissue, and accumulating basic data for subsequent targeted formulation development.

 

It is also a core ingredient for constructing animal models of obesity, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease, and for conducting related mechanism investigations. Researchers administered the substance to classic experimental animals such as diet-induced obese mice and spontaneously obese rhesus monkeys. The substance rapidly reduced subcutaneous and visceral fat content, simultaneously lowering body weight, blood glucose, and blood lipid levels, and improving insulin resistance. Based on this mechanism, researchers can directly verify the role of excessive adipose tissue accumulation in the development of metabolic disorders and analyze the series of chain reactions in systemic physiological metabolism after fat ablation.

 

As a key lead compound for adipose-targeting vascular peptide drugs, Adipotide Peptide has led a new approach to fat-reducing drug development. Although early clinical trials were terminated due to significant nephrotoxicity, its mechanism of action-inducing apoptosis by cutting off blood supply-breaks the limitations of traditional fat-reducing substance development. Numerous research teams have used the peptide's dual-domain structure as a blueprint for modification, optimizing the target region, apoptosis sequence, and linker fragments. This improves tissue targeting precision while reducing toxic side effects on normal organs, continuously developing a new generation of safe and effective derivatives and advancing targeted fat-reducing therapies.

This peptide also plays an important role in research at the intersection of obesity and oncology. Modern research has confirmed that excessively accumulated white adipose tissue continuously secretes inflammatory factors and growth factors, indirectly promoting the occurrence and progression of tumors such as prostate cancer and breast cancer. By using adipotide peptides to reduce total body fat and decrease the release level of adipose-derived bioactive substances, it is possible to effectively observe the impact of adipose tissue on tumor growth, explore the pathogenesis and feasible intervention methods of obesity-related tumors, and expand the application boundaries of peptide raw materials.

🎯Targeted binding → Internalization → Mitochondrial damage → Angiogenesis → Fat necrosis

Adipotide peptide exerts its efficacy through a complete and hierarchical mechanism, from targeted recognition in the bloodstream to intracellular biochemical reactions, and finally to changes at the tissue and systemic levels. It precisely targets the adipose-vascular system throughout the process, without interfering with central nervous system function or affecting normal tissue function, demonstrating a highly specific action logic.

 

Once the peptide enters the bloodstream, its N-terminal cyclic targeting structure, relying on surface charge and hydrophobic interactions, specifically recognizes and binds to receptor complexes on the surface of white adipose vascular endothelial cells. These specific receptors are concentrated on the inner walls of adipose microvessels; similar target sites are rarely found in the endothelium of blood vessels in other organs. This characteristic allows the peptide molecule to accumulate in large quantities around adipose tissue, avoiding the adverse effects of widespread off-target effects from the source.

 

After binding, the receptor-peptide complex enters the cytoplasm of endothelial cells via clathrin-mediated endocytosis, releasing the complete peptide chain into the cell interior. At this point, the apoptotic peptide segment at the C-terminus, composed of D-amino acids, begins to function. Relying on its positive charge, it penetrates the mitochondrial membrane structure and inserts into the phospholipid bilayer of the inner mitochondrial membrane, directly disrupting the membrane integrity and normal membrane potential, causing mitochondrial swelling and structural rupture.

 

After mitochondrial damage and rupture, various pro-apoptotic substances, such as cytochrome C and apoptosis-inducing factors, are released into the cytoplasm, activating a cascade of caspase family proteins and formally initiating the programmed cell death process in vascular endothelial cells. Following the successive apoptosis of numerous adipose microvascular endothelial cells, the entire microvascular network gradually collapses, completely severing the blood supply channels of adipose tissue, leading to a persistent ischemic and hypoxic environment.

 

Deprived of oxygen and nutrient supply, adipocytes cannot maintain normal physiological activities, subsequently undergoing secondary apoptosis and tissue necrosis. The overall volume and weight of adipose tissue decrease rapidly, with a particularly pronounced reduction in visceral fat. The necrotic adipose tissue is gradually phagocytosed, decomposed, and cleared by macrophages. The short-term inflammatory response that occurs during this process gradually subsides as tissue clearance is completed, and the chronic inflammatory state of adipose tissue is improved.

 

After the total body fat decreases, the secretion of inflammatory factors and free fatty acids by adipose tissue is significantly reduced. Systemic insulin sensitivity gradually recovers, blood sugar and blood lipid levels return to normal, liver steatosis is alleviated, and various metabolic disorders are systematically corrected. This mechanism of action simply reduces the actual number of fat cells, rather than temporarily shrinking their volume. Therefore, the fat-reducing effect is long-lasting and less prone to rebound. Furthermore, it does not interfere with the appetite control center, thus avoiding common side effects such as anorexia and palpitations.

🔭The challenge of nephrotoxicity and the translational prospects of combination therapies

Despite the promising potential of Adipotide peptide in weight loss and metabolic improvement, its clinical translation has been hampered by nephrotoxicity. Between 2011 and 2015, adipotide peptide underwent a series of Phase I clinical trials. These studies aimed to evaluate its safety and tolerability in obese or overweight patients with type 2 diabetes and to explore its initial weight loss effects. Results confirmed that adipotide did indeed lead to some degree of weight loss and improved insulin resistance. However, safety data showed that some subjects experienced dose-limiting nephrotoxicity, primarily manifested as elevated serum creatinine, proteinuria, and elevated biomarkers of renal tubular damage. Renal biopsy revealed increased apoptosis of renal tubular epithelial cells, which was associated with the expression profile of prohibitin in renal vessels. Therefore, the clinical development of adipotide peptide was suspended or terminated after Phase I trials.

The patent portfolio and modification strategies for adipotide peptide primarily focus on reducing nephrotoxicity. Subsequent development of second-generation molecules primarily involves shortening the half-life, altering linkers to modify metabolic pathways, or introducing additional "shielding groups" into the homing peptide. Another strategy is to develop "prodrug" forms that are specifically activated only in the adipose tissue microenvironment and remain inert in the kidneys. Fusing adipotide peptide with anti-prohibitin antibodies using antibody-drug conjugate technology can further improve targeting, but this direction is still in the early stages of exploration.

 

The combined application of adipotide peptide with GLP-1 receptor agonists is a very promising translational direction. GLP-1 drugs such as semaglutide achieve weight loss by centrally suppressing appetite, but weight rebound is common after discontinuation. Adipotide peptide, on the other hand, works by physically disrupting adipose tissue; the combination of the two may produce a synergistic effect in terms of weight loss and weight maintenance. Nephrotoxicity and immunogenicity are the core challenges facing the development of adipotide peptide. Since adipotide is a completely synthetic peptide, it should theoretically not induce strong anti-drug antibodies like protein drugs. However, low titers of anti-Adipotide antibodies were still detected in preclinical studies, and their clinical significance remains unclear.

 

From the perspective of active pharmaceutical ingredients (APIs), Adipotide peptide is a high-purity, high-difficulty peptide raw material. The efficiency of its cyclization step and the stability of the linker are the core technological barriers in process development. The clinical value of Adipotide in obesity and type 2 diabetes is currently still in the "validated efficacy, risks remain" stage. For current pharmaceutical research and development, the "vascular ablation" strategy it represents forms an interesting, albeit misaligned, competition with the booming GLP-1 class of drugs.

Conclusion

Adipotide peptide is a chimeric peptide that combats obesity and insulin resistance by inducing apoptosis in vascular endothelial cells of white adipose tissue. Its N-terminal cyclic homing peptide endows it with the ability to target prohibitin, while its C-terminal (KLAKLAK)₂ cationic peptide acts as the weapon to execute apoptosis. Although its Phase I clinical trial was temporarily suspended due to reversible nephrotoxicity, the robust weight loss of 10%-15% and significant metabolic improvement in rhesus monkey models indicate that its vascular-targeting strategy still has enormous translational potential. Optimizing dosage, modifying its structure, or using combination therapies to mitigate its nephrotoxicity will be key to whether this "adipose-vascular ghost" can return to the clinical forefront.

 

Xi'an Faithful BioTech Co., Ltd. cordially invites European pharmaceutical companies to partner with us for high-quality, competitively priced Adipotide peptide. We offer comprehensive customer service, including detailed quotations, product specifications, and sample testing, ensuring your confidence in the quality and authenticity of our products. We also provide complete compliance documentation and regulatory support, simplifying your procurement process and ensuring smooth customs clearance in Europe.

Contact our experienced team today at allen@faithfulbio.com to discuss your specific needs and learn why leading European companies choose Faithful as their trusted Adipotide peptide supplier.

References

1. Barnhart, K. F., et al. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine, 3(108), 108ra112.
2. Adipotide (PTD-DBM). (n.d.). AbMole BioScience (M54537).
3. Prohibitin-targeting peptide (Adipotide). (n.d.). Abcam (ab284383).
4. Adipotide (CKGGRAKDC-GG-(KLAKLAK)2). (n.d.). CPC Scientific (PEP-1335).
5. Adipotide (PTD-DBM). (n.d.). MedChemExpress (HY-P1198).
6. Kolonin, M. G., et al. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine, 10(6), 625-632.
7. Adipotide (PTD-DBM). (n.d.). TargetMol (T22106).